// App-Quantinova.ai

3003 : Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.

Researchers

Presenter

  • Luis A. Diaz

Principal Investigators

  • Hao Wang

  • Bjarne Bartlett

  • Holly Kemberling

  • Aleksandra Eyring

  • Nilofer Saba Azad

  • Tianna Dauses

  • Dan Laheru

  • James J. Lee

  • Todd S. Crocenzi

  • Richard M. Goldberg

  • George A. Fisher

  • Tim F. Greten

  • Christian Frederick Meyer

  • Amanda Nickles Fader

  • Deborah Kay Armstrong

  • Minori Koshiji

  • Bert Vogelstein

  • Dung T. Le

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • University of Pittsburgh, Pittsburgh, PA

  • Providence Cancer Center, Portland, OR

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Johns Hopkins, Baltimore, MD

  • The Johns Hopkins Hospital, Baltimore, MD

  • Merck & Co. Inc., Rahway, NJ

  • Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, Baltimore, MD

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01876511

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved